<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0202221671
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Amaglime-Met
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METFORMIN HYDROCHLORIDE,GLIMEPIRIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500,2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        19.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="(Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            (Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 437]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QA10BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        A10BB12
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>amaglime-met is a medicine taken by mouth to help lower blood sugar. amaglime-met is used with diet<br />and physical exercise, to treat a certain form of diabetes (type 2 diabetes mellitus):<br />- In case the use of Glimepiride or Metformin alone does not control your blood glucose level, in place of<br />taking the combination of Glimepiride tablet with a Metformin tablet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take amaglime-met<br />- if you have insulin-dependent diabetes (type 1 diabetes mellitus),<br />- if you have diabetic ketoacidosis (a complication of diabetes when your acid level is raised in your body<br />and you may have some of the following signs: fatigue, feeling sick (nausea), frequent urination and<br />muscular stiffness),<br />- if you are in a diabetic pre-coma,<br />- if you are allergic (hypersensitive) to Glimepiride or Metformin hydrochloride, or any of the other<br />ingredients of amaglime-met (see section 4), to sulphonamide (medicines for bacterial infections such as<br />sulfamethoxazole), other sulfonylureas (medicines used to lower your blood sugar such as glibenclamide),<br />- if you are pregnant, planning to get pregnant or are breast-feeding,<br />- if you have or have had lactic acidosis (an increase in the amount of lactic acid in the body),<br />- if you have a severe kidney disease or kidney disorder,<br />- if you have recently had a heart attack or are treated for heart failure, or have severe circulatory problems<br />or difficulty in breathing,<br />- if you have a liver disorder,<br />- if you drink a lot of alcohol,<br />- if you have a severe infection or are dehydrated,<br />- if you are going to have an examination such as X-ray or scan involving the injection of contrast medicines<br />that contain iodine into your bloodstream. You will need to stop taking amaglime-met at the time of and for<br />a few days after the procedure.<br />Warnings and precautions<br />Pleas follow closely the instructions for dosage, monitoring, (blood and/or urine tests), diet and physical<br />activity (physical work and exercise) as discussed with your doctor.<br />Talk to your doctor or pharmacist before taking your medicine if you are recovering from an injury,<br />operation, infections with fever, or from other forms of stress, inform your doctor as temporary<br />change of treatment may be necessary.<br />Important information about lactic acidosis<br />Lactic acidosis is an increase in the amount of lactic acid in the blood. It is a rare, but serious, side effect<br />of the Metformin.<br />The symptoms of lactic acidosis include: rapid breathing, stomach pain, nausea, vomiting, and feeling cold.<br />If you experience some of these symptoms, stop taking amaglime-met and contact your doctor<br />immediately.<br />Important information about hypoglycaemia (low blood sugar):<br />When you take amaglime-met, you may get hypoglycaemia (low blood sugar). Please see below for<br />additional information about hypoglycaemia, its signs and treatment.<br />The following factors could increase the risk of you getting hypoglycaemia:<br />- Undernourishment, irregular mealtime, or missed or delayed meal or period of fasting,<br />- If you increase your body exercise and you don&rsquo;t eat enough food or eat food containing less carbohydrate</p><p>than normal,<br />- Change in your diet,<br />- Drinking alcohol (especially when you skip a meal),<br />- Having decrease kidney function<br />- Having severe liver disease,<br />- If you suffer from certain uncompensated hormone induced disorders: disorders of thyroid glands of the<br />pituitary gland or adrenal cortex,<br />- Taking certain other medicines (see section 2 under &ldquo;other medicines and amaglime-met&rdquo;,<br />- Taking more amaglime-met than needed.<br />If such risk factors for hypoglycaemia are present, it may be necessary to adjust the dosage of amaglimemet,<br />talk with your doctor or pharmacist. This also applies whenever illness occurs during therapy or any<br />life-style changes.<br />Symptoms of hypoglycaemia:<br />The symptoms of hypoglycaemia (see section 4) may be milder or absent in those situations where hypoglycaemia<br />develops gradually, in the elderly, and in patient with a certain type or nervous disease (autonomic<br />neuropathy) or those receiving treatment with other medications called beta blockers, clonidine, reserpine,<br />guanethidine, or other sympathomimetics.<br />Treating hypoglycaemia:<br />In most cases the signs of reduced blood sugar vanish very quickly when you consume some form of sugar,<br />e.g. sugar cubes, sweet juice, or sweetened tea. You should therefor always take some form of sugar with<br />you (e.g. sugar cubes). Remember that artificial sweeteners are not effective.<br />Please contact your doctor or go to the hospital if taking sugar does not help or if the symptoms recur.<br />Laboratory tests<br />The level of sugar in your blood or urine should be checked regularly. Your doctor may also take blood tests<br />to monitor your blood cell levels and liver function.<br />Lowering of the hemoglobin level and breakdown of red blood cell (hemolytic anemia) can occur in patients<br />missing the enzyme glucose-6-phosphate dehydrogenase.<br />Kidney function:<br />Your kidney function should be measured before starting the treatment and monitored regularly:<br />&bull; at least once a year in patients with normal kidney function.<br />&bull; At least two or four times a year in patients with kidney disease and elderly subjects.<br />Pay special attention to situation where your kidney function may become impaired, such as when starting<br />new medicine for: lowering blood pressure, water retention or treatment with a medicine used for pain and<br />inflammation (known as a non-steroidal anti-inflammatory).<br />Surgery or injection of contrast medicines that contain iodine for examinations<br />If you need to have a surgery or if you need to have an injection of contrast medicines that contain iodine<br />into your bloodstream, for example for examinations such as X-ray or scan, you should stop taking<br />amaglime-met for a certain period of time before and after the examination or surgery. Your doctor will<br />decide whether you need any other treatment for this time. It is important that you follow your doctor&rsquo;s instructions precisely.</p><p>Children and adolescents<br />amaglime-met has not been studied in children and adolescents who are under 18 years of age.<br />Other medicines and amaglime-met<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Your doctor may wish to change your dose of amaglime-met if you are taking other medicines, which may<br />weaken or strengthen the effect of amaglime-met on the level of sugar in your blood.<br />The following medicines can increase the blood sugar lowering effect of amaglime-met. This can lead to a<br />risk of hypoglycaemia (low blood sugar):<br />&bull; Other medicinal products to treat diabetes mellitus (such as insulin or other antidiabetics),<br />&bull; Medicinal products to treat pain and inflammation (phenylbutazone, azapropazone, oxyphenbutazone,<br />aspirin-like-medicine).<br />&bull; Medicinal products to treat urinary infections (such as some long acting sulphonamides),<br />&bull; Medicinal products to treat bacterial and fungal infections (tetracyclines, chloramphenicol, fluconazole,<br />miconazole, quinolones, clarithromycin),<br />&bull; Medicinal products to inhibit blood clotting (coumarin derivatives such as warfarin),<br />&bull; Medicinal products supporting muscle build up (anabolic),<br />&bull; Medicinal products used for male sex hormone replacement therapy,<br />&bull; Medicinal products to treat depression (fluoxetine, MAO-inhibitors),<br />&bull; Medicinal products lowering high cholesterol level (fibrates),<br />&bull; Medicinal products lowering high blood pressure (ACE inhibitors),<br />&bull; Medicinal products called anti-arrhythmic agents used to control abnormal heartbeat (disopyramide),<br />&bull; Medicinal products to treat gout (allopurinol, probenecid, sulfinpyrazone),<br />&bull; Medicinal products to treat cancer (cyclophosphamide, ifosfamide, trofosfamide),<br />&bull; Medicinal products used to reduce weight (fenfluramine),<br />&bull; Medicinal products to increase circulation when given in a high dose intravenous infusion (pentoxifylline),<br />&bull; Medicinal products to treat nasal allergies such as hay fever (tritoqualine),<br />&bull; Medicinal products called sympatholytic to treat high blood pressure, heart failure, or prostate symptoms.</p><p>The following medicines may decrease the blood sugar lowering effect of amaglime-met. This can lead to a<br />risk of hyperglycaemia (high blood sugar level):<br />&bull; Medicinal products containing female sex hormones (oestrogens, progestogens),<br />&bull; Medicinal products supporting urine production (thiazide diuretics),<br />&bull; Medicinal products used to stimulate the thyroid gland (such as levothyroxine),<br />&bull; Medicinal products to treat allergies and inflammation (glucocorticoids),<br />&bull; Medicinal products to treat severe mental disorders (chlorpromazine and other phenothiazine derivatives),<br />&bull; Medicinal products used to raise heartbeat, to treat asthma or nasal congestion, coughs and colds, used to<br />reduce weight, or used in life-threatening emergencies (adrenaline and sympathomimetics),<br />&bull; Medicinal products to treat high cholesterol level (nicotinic acid),<br />&bull; Medicinal products to constipation when they are used long term (laxatives),<br />&bull; Medicinal products to treat seizure (phenytoin),<br />&bull; Medicinal products to treat nervousness and sleep problems (barbiturates),<br />&bull; Medicinal products to treat increased pressure in the eye (acetazolamide),<br />&bull; Medicinal products to treat high blood pressure or lowering blood sugar (diazoxide),<br />&bull; Medicinal products to treat infections, tuberculosis (rifampicin),<br />&bull; Medicinal products to treat severe low blood sugar levels (glucagon),<br />&bull; Medicinal products to treat asthma (beta-2 agonists such as salbutamol).<br />The following medicinal products can increase or decrease the blood sugar lowering effect of amaglimemet:<br />&bull; Medicinal products to treat stomach ulcers (called H2 antagonists),<br />&bull; Medicinal products to treat high blood pressure or heart failure such as beta-blockers, clonidine, guanethidine<br />and reserpine. These can also hide the signs of hypoglycaemia, so special care is needed when<br />taking these medicines.<br />amaglime-met may either increase or weaken the effects of the following medicines:<br />&bull; Medicinal products inhibiting blood clotting (coumarin derivatives such as warfarin).</p><p>&bull; Colesevelam, a medicine used to reduce cholesterol, has an effect on the absorption of amaglime-met. To<br />avoid this effect, you should be advised to take amaglime-met at least 4 hours before colesevelam.<br />Iodinated contrast agents:<br />A build-up of acid in your blood (known as lactic acidosis) may occur if you take iodinated contrast materials<br />for a special examination such as X-ray or scan, you should stop taking amaglime-met for a certain period<br />of time before and after the examination (see section 2 under &ldquo;Warnings and precautions&rdquo;<br />amaglime-met with alcohol<br />You should avoid drinking alcohol and using alcohol-containing medicines. Alcohol intake may increase or<br />decrease the blood-sugar-lowering action of amaglime-met in an unpredictably way. Alcohol intake also<br />increase the risk of lactic acidosis.<br />Pregnancy and breastfeeding<br />You should not use amaglime-met if you are pregnant or breastfeeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor or your pharmacist for advice before taking this medicine.<br />Driving and using machines<br />Your ability to concentrate or react may be impaired if your blood sugar is lowered (hypoglycaemia) or<br />raised (hyperglycaemia) or if you develop visual problems as a result of such conditions. Bear in mind that<br />you could endanger yourself or others (e.g. when driving a car or using machines). Ask your doctor whether<br />you can drive a car if you:<br />&bull; have frequent episodes of hypoglycaemia,<br />&bull; have fewer or no warning signals of hypoglycaemia.<br />amaglime-met contains lactose.<br />If you have been told by your doctor that you cannot tolerate some sugars, contact your doctor before taking<br />amaglime-met.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or<br />pharmacist if you are not sure.<br />The dose of amaglime-met depends on your needs, condition and results of blood and urine sugar tests<br />and is determined by your doctor. Do not take more tablets than your doctor has prescribed.<br />Recommended dose<br />It is recommended to start the treatment with the lowest effective dose and your doctor might increase the<br />dose depending on your blood glucose level.<br />When switching from combination therapy of Glimepiride plus Metformin as separate tablets, amaglime-met<br />should be administered on the basis of the dosage currently being taken.<br />- If your weight changes or if you change your lifestyle, or you are in a stress situation this may require<br />changed amaglime-met doses, therefore inform your doctor.<br />- If you feel the effect of your medicine is too weak or too strong do not change the dose yourself but ask<br />your doctor.<br />How to take this medicine<br />amaglime-met should be taken by mouth immediately before or with the meals. Swallow the tablets whole<br />with about half glass of water.<br />If you take more amaglime-met than you should<br />Hypoglycaemia: if you happen to have taken too much amaglime-met or an additional dose there is a<br />danger of hypoglycaemia (for the signs of hypoglycaemia, see section4) and therefore you should instantly<br />consume enough sugar (e.g. a small bar of sugar cubes, sweet juice, sweetened tea) and inform a doctor<br />immediately.<br />When treating hypoglycaemia due to accidental intake in children, the quantity of sugar given must be<br />carefully controlled to avoid the possibility of producing dangerous hyperglycaemia.<br />Person in state of unconsciousness must not be given food or drink.<br />Since the state of hypoglycaemia may last for some time it is very important that the patient is carefully<br />monitored until there is no more danger. Admission into a hospital may be necessary, also as a measure of<br />precaution. Show the doctor the package or remaining tablets, so the doctor knows what has happen taken.<br />Severe cases of hypoglycaemia accompanied by loss of consciousness and severe neurological failure<br />are cases for medical emergency requiring immediate medical treatment and admission into hospital.<br />It should be ensured that there is always pre-informed person that can call a doctor immediately if this<br />happens to you.<br />Lactic acidosis: Because this medicine contains metformin, this may lead you also to lactic acidosis (see<br />section 2 under &ldquo;warnings and precautions&rdquo;). This is medical emergency requiring treatment in hospital.<br />Please consult your doctor or pharmacist immediately.<br />If you forget to take amaglime-met<br />If you forget to take your dose on time, take your dose with your next meal. Do not take a double dose to<br />make up for a forgotten dose.<br />If you stop taking amaglime-met<br />If you interrupt or stop the treatment you should be aware that the desired blood sugar lowering effect is not<br />achieved or that the disease will get worse again.<br />If you have any further questions on the use of this medicine, ask your doctor, pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Tell your doctor immediately if you experience any of the following symptoms:<br />&bull; Hypoglycaemia (see also section 2 under &ldquo;warnings and preclusions&rdquo;):<br />Due to the blood-sugar-lowering action of amaglime-met, hypoglycaemia may occur, and may last for some<br />time.<br />Sings of hypoglycaemia include:<br />- Hunger pangs, headache, nausea, vomiting, sluggishness, disordered sleep, restlessness aggression,<br />impaired concentration, reduced alertness and reaction time, depression, confusion, speech and visual<br />disorders, slurred speech, shakiness, partial paralysis, sensory disturbance, dizziness and helplessness.<br />- The following signs may also occur: sweating, clammy skin, anxiety, accelerate heartbeat, high blood<br />pressure, palpitations, sudden strong pain in the breast that may radiate into neighbouring areas (angina<br />pectoris and cardiac arrhythmias).<br />- If blood sugar levels continue to drop you may suffer from considerable confusion (delirium), develop convulsions,<br />loss of self-control, breathing may be shallow and your heartbeat slowed down, you may fall into<br />unconsciousness. The clinical picture of a severe reduced blood sugar level may resemble that of a stroke.<br />Treating hypoglycaemia:<br />In most cases the signs of reduced blood sugar vanish very quickly when you consume some form of sugar,<br />e.g. sugar cubes, sweet juice, sweetened tea. Contact your doctor or go to the hospital if taking sugar<br />does not help or if the symptoms recur.<br />&bull; Allergic reactions (including inflammation of blood vessels, often with skin rash) which may develop into<br />serious reactions with difficulty in breathing, fall in blood pressure and sometimes progressing to shock. If<br />hives or rash occurs, a physician must be notified immediately.<br />&bull; Allergy (hypersensitivity) of the skin such as itching, rash, hives and increased sensitivity to sun. some mild<br />allergic reactions may develop into serious reactions.<br />&bull; Abnormal liver function including yellowing of the skin and eyes (jaundice), problems with the bile flow<br />(cholestasis), increased liver enzymes, inflammation of the liver (hepatitis) or liver failure.<br />&bull; Digestive disorders: feeling of being sick, diarrhoea, feeling full or bloated, abdominal pain and loss of appetite.<br />&bull; Taste disorders: Taste of metal in your mouth.<br />&bull; Blood disorder: Decrease in the number of blood cells:<br />- Blood platelets (which increases risk of bleeding or bruising including severe unusual bleeding or bruising<br />under the skin).<br />- White blood cells (which can make infections more likely).<br />- Red blood cells (which can make the skin pale and cause weakness or breathlessness).<br />These problems generally get better after you stop taking amaglime-met.<br />&bull; Decrease in the amount of sodium level in your blood (shown by blood tests).<br />&bull; Decreased vitamin B12 levels: Low levels of vitamin B12 may be seen. Therefor if needed, monitor serum B12 levels.<br />&bull; Eye disorders: problems with your sight may occur when beginning treatment with amaglime-met.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Store below 30&deg;C.<br />&bull; Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date<br />refers to the last day of that month.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw<br />away medicines if you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substances are Glimepiride 2mg and Metformin hydrochloride 500mg.<br />&bull; The other ingredients are: Microcrystalline Cellulose, Crosspovidone, Sodium Starch Glycolate, Povidone<br />K30, Magnesium Stearate, Opadry White and Lactose Monohydrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                amaglime-met film-coated tablets are white capsule shaped, biconvex filmcoated tablet debossed with
“C26” on one side and plain on other side.
Packed in 4 blisters (7 tablets / blister).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Middle East Pharmaceutical Industries Co Ltd (Avalon Pharma)<br />P.O.Box 4180 Riyadh 11491<br />2nd Industrial City, Riyadh, Kingdom of Saudi Arabia<br />Tel: +966 (11) 2653948 -2653427<br />Fax: +966 (11) 2654723</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                08/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>أماجلايم-مت هو دواء يُؤخذ عن طريق الفم للمساعدة في خفض نسبة السكر في الدم. يُستخدم أماجلايم-مت لعلاج نوع معين من أنواع داء<br />السكري )داء السكري من النوع الثاني( بالإضافة إلى اتباع نظام غذائي وممارسة الرياضة البدنية:<br />&bull; عندما يكون استعمال جليميبيريد وحده أو الميتفورمين وحده غير كافياً لضبط سكر الدم، يُستخدم كبديل للمعالجة المشتركة جليميبيريد +<br />ميتفورمين عندما يؤخذان بشكل أقراص منفصلة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول أماجلايم-مت في الحالات التالية:<br />- إذا كنت تُعاني من داء السكري المعتمد على الأنسولين )داء السكري من النوع الأول(.<br />- إذا كنت تُعاني من حموضة الدم الكيتونية )أحد مضاعفات داء السكري يتسبب في ارتفاع مستويات الحمض في الجسم، وقد تظهر لديك بعض<br />العلامات الآتية: تعب، وشعور بالغثيان، وكثرة التبول، وتيبُّس العضلات(.<br />- إذا كنت في حالة ما قبل الغيبوبة السكرية.<br />- إذا كانت لديك حساسية )فرط تحسس( من جليميبيريد أو ميتفورمين هيدروكلورايد، أو أي من المكونات الأخرى لأقراص أماجلايم-مت<br />)راجع القسم 4( أو السلفوناميد )دواء للعدوى البكتيرية مثل: سلفاميثوكسازول( أو مركبات السلفونيليوريا الأخرى )أدوية تُستخدم في خفض<br />سكر الدم مثل: جليبنكلاميد(.<br />- إذا كنتِ حاملاً أو تُخططين للإنجاب أو كنتِ مُرضعة.<br />- إذا كنت تُعاني من حموضة الدم الكيتونية )زيادة في كمية حمض اللاكتيك في الجسم(.<br />- إذا كنت تُعاني من قصور شديد في الكلى أو اضطراب في الكلى.<br />- إذا أصبت مؤخرًا بأزمة قلبيَّة أو عولجت من قصورٍ في القلب أو لديك مشاكل في الدورة الدمويَّة أو صعوبة في التنفس.<br />- إذا كنت تعاني من اضطرابات في الكبد.<br />- إذا كنت تشرب الكثير من الكحول.<br />- إذا كنت تعاني من عدوى شديدة أو كنت تعاني من الجفاف.<br />- إذا كنت ستخضع لفحص مثل: الفحص بالأشعة السينيَّة أو فحص يتضمن حقن أدوية تباين تحتوي على اليود في مجرى الدم. فسوف تحتاج<br />للتوقُّف عن تناول أماجلايم-مت في وقت هذا الإجراء وبعد عدة أيام من الإجراء.<br />تحذيرات واحتياطات<br />يُرجى اتباع التعليمات بدقة فيما يتعلق بالجرعة والمراقبة و)اختبارات الدم و/أو البول( والأنشطة البدنية )العمل البدني والتمارين الرياضية(<br />وفقًا لما قُمت بمناقشته مع طبيبك.<br />تحدَّث مع طبيبك أو الصيدلي قبل تناول هذا الدواء إذا كنت تتعافى من إصابة أو عملية جراحية أو عدوى مصحوبة بحمى أو أي شكلٍ آخر<br />من أشكال الإجهاد، أخبر طبيبك لأن التغيير المُؤقت في العلاج قد يكون ضروريًّا.<br />معلومات مهمة عن حموضة الدم الكيتونية<br />حموضة الدم الكيتونية هي زيادة في كمية حمض اللاكتيك في الدم. وهو أحد الأعراض الجانبية النادرة ولكن خطيرة للميتفورمين.<br />تتضمن أعراض حموضة الدم الكيتونية: سرعة التنفُّس وآلام المعدة والغثيان والقيء والشعور بالبرد.<br />إذا شعرت ببعضٍ من تلك الأعراض توقَّف عن تناول أماجلايم-مت واتَّصل بطبيبك على الفور.<br />معلومات مهمة عن انخفاض سكر الدم:<br />قد تتعرض لنقص سكر الدم )انخفاض سكر الدم( عند تناول أماجلايم-مت. يُرجى النظر أدناه للحصول على المزيد من المعلومات عن نقص<br />سكر الدم وعلاماته وعلاجه.<br />يُمكن للعوامل التالية أن تزيد من خطر إصابتك بانخفاض سكر الدم:<br />- نقص التغذية أو عدم انتظام أوقات الوجبات أو عدم تناول الوجبة أو تأخيرها أو أثناء فترة الصيام.<br />- إذا زدت من ممارسة التمارين الرياضية ولم تتناول كمية كافية من الطعام، أو تناولت طعامًا يحتوي على كميات من الكربوهيدرات<br />أقل من المعتاد.<br />- تغيير النظام الغذائي.<br />- شرب الكحول )خاصة عندما تتخطى تناول أحد الوجبات(.<br />- انخفاض في وظائف الكلى.<br />- إذا كنت تُعاني من مرضٍ حادٍّ في الكبد.<br />- إذا كنت تعاني من اضطرابات بسبب عدم تعويض هرمون معين بما في ذلك: اضطرابات الغدة الدرقية أو الغدة النخامية أو قشرة الغدة<br />الكظرية.<br />.)&raquo; الأدوية الأخرى وأماجلايم-مت &laquo; - إذا كنت تتناول أدوية أخرى معينة )راجع القسم 2<br />- تناول أماجلايم-مت أكثر مما تحتاجه.<br />عند وجود عوامل خطر قد تُسبب انخفاض سكر الدم، فقد يكون من الضروري تعديل جرعة أماجلايم-مت، تحدَّث مع الطبيب أو الصيدلي<br />بخصوص ذلك. ينطبق ذلك أيضًا عند حدوث مرض أثناء العلاج، أو عند إجراء أي تغييرات في نمط الحياة.</p><p>أعراض انخفاض سكر الدم:<br />قد تكون أعراض انخفاض سكر الدم )راجع القسم 4( أخف أو غير موجودة في الحالات التي يظهر فيها انخفاض سكر الدم بصورة تدريجية،<br />عند كبار السن، ولدى المرضى المُصابين بأنواع معيَّنة من الأمراض العصبية )الاعْتِلاَلٌ العَصَبِيٌّ المُسْتَقِلِّي( أو الأشخاص الذين يتلقُّون العلاج<br />بأدوية أخرى تسمى حاصرات بيتا أو الكلونيدين أو الريزيربين أو الغوانيثيدين أو المحاكيات الودية الأخرى.<br />علاج انخفاض سكر الدم:<br />في معظم الحالات تختفي علامات انخفاض سكر الدم بسرعة كبيرة عند تناول شكل من أشكال السكر، على سبيل المثال: مكعبات سكر أو<br />عصير حلو أو شاي مُحلى؛ لذلك يجب أن تحمل معك دائمًا شكلاً من أشكال السكر مثل: )مكعبات السكر(. تذكَّر أن المُحليات الصناعية<br />ليست فعَّالة.<br />يُرجى الاتِّصال بالطبيب أو الذهاب إلى المستشفى إذا لم يُساعدك تناول جرعة من السكر أو عند تكرار الأعراض.<br />الفحوصات المخبرية<br />يجب فحص مستوى السكر في الدم أو البول بصورة منتظمة. قد يقوم طبيبك كذلك بإجراء اختبارات للدم لمراقبة مستويات سكر الدم<br />ووظائف الكبد.<br />قد يحدث انخفاض في مستويات الهيموجلوبين، وتكسُّر في كرات الدم الحمراء )فَقْرُ الدَّمِ الانْحِلالِي( لدى المرضى الذين يفتقرون إلى إنزيم<br />نازعة هيدروجين الجلوكوز 6 فوسفات.<br />وظائف الكلى:<br />يجب قياس وظائف الكلى لديك قبل بدء العلاج، ومراقبتها بصورة منتظمة:<br />&bull; مرة واحدة على الأقل بالنسبة للمرضى الذين لديهم وظائف الكلى طبيعية.<br />&bull; مرتان أو أربع مرات سنويًّا بالنسبة للمرضى الذين يُعانون من أمراض الكلى وكبار السن.<br />أعطِ اهتمامًا خاصًّا للحالات التي قد تتسبب في إضعاف وظائف الكلى لديك؛ كأن تبدأ في استخدام دواء جديد ل: خفض ضغط الدم، أو احتباس<br />الماء أو العلاج بأدوية لتخفيف الألم وعلاج الالتهابات )معروفة باسم مضادات الالتهابات غير الستيرويدية(.<br />الجراحة أو الحقن بأدوية التباين التي تحتوي على اليود لإجراء أحد الفحوص<br />إذا كنت في حاجة إلى إجراء جراحة، أو إذا احتجت للحقن بأحد أدوية التباين التي تحتوي على اليود في مجرى الدم لإجراء أحد الفحوص، مثل:<br />الفحص بالأشعة السينية أو إجراء مسحٍ، فينبغي عليك التوقف عن تناول أماجلايم-مت لفترة معينة قبل وبعد إجراء الفحص أو الجراحة. وسوف<br />يُقرر طبيبك ما إذا كنت في حاجة لأي علاج آخر خلال تلك الفترة. من الضروري أن تتبع تعليمات الطبيب بدقَّة.<br />الأطفال والمراهقون<br />لم يتم دراسة تأثير أماجلايم-مت على الأطفال والمراهقين الأقل من 18 عامًا.<br />الأدوية الأخرى وأماجلايم-مت<br />أبلغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّ أدوية أخرى. قد يرغب طبيبك في تغيير جرعتك من أماجلايم-مت<br />إذا كنت تتناول أدوية أخرى قد تتسبب في إضعاف أو تقوية تأثير أماجلايم-مت على مستوى السكر في دمك. قد تؤدي الأدوية التالية إلى زيادة<br />تأثير أماجلايم-مت الخفض لسكر الدم مما يعرضك لخطر انخفاض مستوى سكر الدم:<br />&bull; الأدوية الأخرى التي تُستخدم في علاج داء السكري، مثل: )الأنسولين وأدوية علاج داء السكري الأخرى(.<br />&bull; الأدوية التي تُستخدم في علاج الألم والالتهابات )فينيلبيوتازون وآزابروبازون وأوكسيفينبوتازون والأدوية التي تُشبه الأسبرين(.<br />&bull; الأدوية التي تُستخدم في علاج التهابات المسالك البولية، مثل: )بعض السلفوناميدات طويلة المفعول(.<br />&bull; الأدوية التي تُستخدم في علاج الالتهابات البكتيرية والفطرية )تتراسيكلين، كلورامفينيكول، فلوكونازول، ميكونازول، الكينولونات،<br />الكلاريثروميسين(.<br />&bull; الأدوية التي تمنع تخثر الدم )مشتقات الكومارين مثل: الوارفارين(.<br />&bull; الأدوية التي تدعم بناء العضلات )البنائية(.<br />&bull; الأدوية التي تُستخدم في العلاج التعويضي للهرمونات الجنسية الذكرية.<br />&bull; الأدوية التي تُستخدم في الاكتئاب )الفلوكسيتين، مثبطات الأوكسيداز الأحادي الأمين(.<br />&bull; الأدوية التي تُخفض المستويات المرتفعة من الكوليسترول )الفايبرات(.<br />&bull; الأدوية التي تُخفض المستويات المرتفعة من ضغط الدم )مثبطات الإنزيم المحول للأنجيوتنسين(.<br />&bull; الأدوية التي تُسمى العوامل المضادة لاضطراب النظم وتُستخدم في السيطرة على ضربات القلب غير طبيعية )ديسوبيراميد(.<br />&bull; الأدوية التي تُستخدم في علاج النقرس )الوبيورينول، بروبنسيد، سولفينبيرازون(.<br />&bull; الأدوية التي تُستخدم في علاج مرض السرطان )سيكلوفوسفاميد، الإيفوسفامايد، تروفوسفاميد(.<br />&bull; الأدوية التي تُستخدم في إنقاص الوزن )فينفلورامين(.<br />&bull; الأدوية التي تُستخدم في زيادة الدورة الدمويَّة عند إعطائها بجرعة عالية في الوريد )البنتوكسيفيلين(.<br />&bull; الأدوية التي تُستخدم في علاج حساسية الأنف مثل: حمى القش )تريتوكوالين(.<br />&bull; الأدوية التي تُسمي داحضات الودي، والتي تُستخدم في علاج ضغط الدم المرتفع أو قصور القلب أو أعراض البروستاتا.<br />قد تُؤدي الأدوية التالية إلى خفض سكر الدم مما يقلل من تأثير أماجلايم-مت. قد يُؤدِّي ذلك إلى خطر تعرُّضك لارتفاع مستوى سكر&nbsp;الدم:<br />&bull; الأدوية التي تحتوي على الهرمون الجنسي الأنثوي )الإستروجين، البروجسترون (.<br />&bull; الأدوية التي تُساعد على إدرار البول )مدرات البول الثيازيدية(.<br />&bull; الأدوية التي تُستخدم في تحفيز الغدة الدرقية، مثل: )ليفوثيروكسين(.<br />&bull; الأدوية التي تُستخدم في علاج الحساسية والالتهابات )الجلوكوكورتيكويد(.<br />&bull; الأدوية التي تُستخدم في علاج الاضطرابات النفسية الشديدة )الكلوربرومازين ومشتقات الفينوثيازين الأخرى(.<br />&bull; الأدوية التي تُستخدم في زيادة ضربات القلب، لعلاج الربو أو احتقان الأنف والسعال ونزلات البرد، والتي تستخدم في خفض الوزن، أو<br />تستخدم في حالات الطوارئ التي تهدد الحياة )الأدرينالين والمحاكيات الودية(.<br />&bull; الأدوية التي تُستخدم في علاج ارتفاع نسبة الكوليسترول )حمض النيكوتينيك(.<br />&bull; الأدوية التي تعالج الإمساك عند استخدامها لفترات طويلة )المليّنات(.<br />&bull; الأدوية التي تُستخدم في علاج نوبات الصرع )الفينيتوين(.<br />&bull; الأدوية التي تُستخدم في علاج العصبية ومشكلات النوم )الباربيتورات(.<br />&bull; الأدوية التي تُستخدم في علاج زيادة ضغط العين )أسيتازولاميد(.<br />&bull; الأدوية التي تُستخدم في علاج ارتفاع ضغط الدم أو في خفض سكر الدم )ديازوكسيد(.<br />&bull; الأدوية التي تُستخدم في علاج الالتهابات والسل )ريفامبيسين(.<br />&bull; الأدوية التي تُستخدم في علاج الانخفاض الشديد في مستويات سكر الدم.<br />&bull; الأدوية التي تُستخدم في علاج الربو )ناهضات بيتا 2 مثل: سالبوتامول(.<br />يُمكن للأدوية التالية أن تتسبب في زيادة أو خفض تأثير أماجلايم-مت المخفض لسكر الدم:<br />.) &bull; الأدوية التي تُستخدم في علاج قرحة المعدة )وتسمى مضاد مستقبلات الهستامين 2<br />&bull; الأدوية التي تُستخدم في علاج ارتفاع ضغط الدم أو قصور القلب مثل حاصرات بيتا والكلونيدين والجوانيثيدين والريزيربين. قد تخفي هذه<br />الأدوية أيضًا علامات نقص السكر في الدم، لذلك يجب توخي الحذر عند تناول هذه الأدوية.<br />قد يتسبب أماجلايم-مت في زيادة أو إضعاف تأثير الأدوية الآتية:<br />&bull; الأدوية المسيلة للدم)مشتقات الكومارين مثل: الوارفارين(.</p><p>&bull; الكوليسيفيلام وهو دواء يُستخدم في خفض نسبة الكوليسترول، ويُؤثر على امتصاص أماجلايم-مت. لتجنُّب هذا التأثير سوف تُنصح بتناول<br />أماجلايم-مت قبل 4 ساعات على الأقل من تناول كوليسيفيلام.<br />مواد التباين التي تحتوى على اليود:<br />قد يحدث تراكم للحمض في الدم )المعروف ب حموضة الدم الكيتونية( إذا تناولت مواد تباين تحتوي على اليود لإجراء فحص معين مثل:<br />الفحص بالأشعة السينية أو إجراء مسح، ينبغي عليك التوقُّف عن تناول أماجلايم-مت لفترة معينة قبل وبعد إجراء الفحص )انظر القسم 2<br />.)&raquo; التحذيرات والاحتياطات &laquo;<br />أماجلايم-مت مع الكحول<br />يجب أن تتجنب شرب الكحول واستخدام الأدوية التي تحتوي على الكحول. قد يُؤدي امتصاص الكحول إلى زيادة أو خفض قدرة أماجلايم-<br />مت على خفض نسبة السكر في الدم بطريقة غير متوقعة. يُؤدي امتصاص الكحول كذلك إلى زيادة خطر التعرُّض لحموضة الدم الكيتونية.<br />الحمل والرضاعة الطبيعية<br />يجب ألا تستخدمي أماجلايم-مت إذا كنتِ حاملاً أو تمارسين الرضاعة الطبيعية أو تظنين أنك قد تكونين حاملاً أو تُخططين لإنجاب طفلٍ.<br />استشيري الطبيب أو الصيدلي لمعرفة رأيه قبل تناول هذا الدواء.<br />القيادة واستخدام الآلات<br />قد تضعف قدرتك على التركيز أو التفاعل عند انخفاض مستويات السكر في الدم )نقص سكر الدم( أو ارتفاعها )فرط سكر الدم( أو إذا حدثت<br />لديك مشكلات في الرؤية بسبب تلك الأمور. تذكَّر أنك قد تُعرِّض نفسك أو تُعرِّض الآخرين للخطر، على سبيل المثال: )عند قيادة السيارة أو<br />استخدام الآلات(. استشر الطبيب عما إذا كنت قادرًا على قيادة السيارة في الحالات التالية:<br />&bull; إذا تعرَّضت للإصابة بنوبات متكررة من نقص السكر في الدم.<br />&bull; إذا كانت علامات التحذير التي تشير إلى إصابتك بنقص سكر الدم قليلة أو معدومة.<br />يحتوي أماجلايم-مت على اللاكتوز<br />إذا أخبرك طبيبك بأنك تُعاني من عدم تحمُّل بعض السكريات فاستشر طبيبك قبل تناول هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول هذا الدواء دائمًا وفقًا لما يُخبرك به الطبيب أو الصيدلي تمامًا. استشر الطبيب أو الصيدلي إذا لم تكن متأكدًا.<br />تعتمد جرعة أماجلايم-مت على احتياجاتك وحالتك ونتائج اختبار السكر والبول في الدم والتي يُحددها طبيبك. لا تتناول أي أقراص تتجاوز<br />الجرعة التي يصفها لك الطبيب.<br />الجرعة الموصى بها<br />يُوصى ببدء العلاج بأقل جرعة فعَّالة، وقد يقوم طبيبك بزيادة الجرعة وفقًا لمستويات الجلوكوز في الدم لديك.<br />عند التحوُّل من العلاج المركب من جليميبيريد وميتفورمين معًا كأقراص منفصلة؛ سيتم إعطاء أماجلايم-مت على أساس الجرعة التي يتم<br />تناولها في الوقت الحالي.<br />- إذا تغير وزنك، أو إذا حدث تغيير في أسلوب حياتك، أو إذا كنت في أحد حالات الإجهاد التي تحتاج لتغيير جرعة أماجلايم-مت؛ قم<br />بإبلاغ طبيبك.<br />- إذا كنت تشعر بأن تأثير الدواء ضعيفٌ جدًّا أو قوي جدًّا فلا تقم بتغيير الجرعة بنفسك ولكن استشر طبييك.<br />كيفية تناول هذا الدواء<br />يجب تناول أماجلايم-مت عن طريق الفم قبل تناول الطعام مباشرة أو مع الوجبات. ابتلع كلَّ قرصٍ بالكامل مع حوالي نصف كوب من الماء.<br />إذا تناولت أماجلايم-مت أكثر مما ينبغي<br />انخفاض سكر الدم: إذا حدث وتناولت الكثير من أماجلايم-مت أو تناولت جرعة إضافية فقد تتعرض لخطر الإصابة بانخفاض سكر الدم )لمعرفة<br />علامات انخفاض سكر الدم راجع القسم 4(، وبالتالي يجب أن تتناول على الفور كمية كافية من السكر، على سبيل المثال: )مكعب صغير من<br />السكر أو عصير حلو أو شاي مُحلّى( وقم بإبلاغ الطبيب على الفور.<br />عند علاج انخفاض سكر الدم الناتج عن تناول الأطفال لهذا الدواء بطريق الخطأ، يجب السيطرة على جرعة السكر المقدمة لهم بعناية شديدة<br />لتجنُّب إمكانية تعرضهم لارتفاع شديد في سكر الدم.<br />يجب عدم إعطاء الأشخاص فاقدي الوعي أيَّ أطعمة أو مشروبات.<br />قد تستمر حالة انخفاض سكر الدم لفترة من الزمن؛ لذلك من المهم جدًّا أن تتم ملاحظة المريض بعناية حتى يزول الخطر. قد يكون إدخال<br />المريض إلى المستشفى أمرًا ضروريًّا كإجراء احترازي. اعرض العبوة أو الأقراص المتبقية على الطبيب ليعرف الطبيب الدواء الذي<br />تناوله عن طريق الخطأ.<br />يُصاحب الحالات الشديدة من انخفاض سكر الدم فقدان الوعي وخلل شديد في الجهاز العصبي، وهي حالات طبية طارئة تتطلب علاجًا طبيًّا<br />فوريًّا ودخول المستشفى. يجب التأكُّد من وجود شخص على علم مُسبق يُمكنه الاتِّصال بالطبيب على الفور إذا حدث لك ذلك.<br />تحذيرات &laquo; حموضة الدم الكيتونية: يحتوي هذا الدواء على الميتفورمين الذي قد يُسبب لك الإصابة بحموضة الدم الكيتونية )راجع القسم 2<br />وهي حالة طبيَّة طارئة تتطلب علاجًا طبيًّا فوريًّا ودخول المستشفى. يُرجى استشارة الطبيب أو الصيدلي على الفور. )&raquo; واحتياطات<br />إذا نسيت تناول أماجلايم-مت<br />إذا نسيت تناول جرعتك في الوقت المحدد، تناول جرعتك مع الوجبة التالية. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.<br />إذا توقفت عن تناول أماجلايم-مت<br />إذا قاطعت العلاج أو توقفت عن تناوله يجب أن تكون مدركًا أن التأثير المرغوب لخفض مستوى سكر الدم لن يتحقق، قد يزداد المرض سوءً.<br />إذا كانت لديك المزيد من الأسئلة بخصوص استخدام هذا الدواء اسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية يُمكن أن يُسبب هذا الدواء آثارًا جانبية على الرغم من عدم حدوثها لكلِ الأشخاص.<br />أبلغ طبيبك على الفور إذا شعرت بأيٍّ من الأعراض الجانبية التالية:<br />:)&raquo; تحذيرات واحتياطات &laquo; &bull; انخفاض سكر الدم )راجع القسم 2<br />قد يتسبب التأثير المخفّض لسكر الدم لأقراص أماجلايم-مت في الإصابة بانخفاض سكر الدم، وقد يستمر ذلك لفترة من الزمن.<br />تتضمن أعراض انخفاض سكر الدم ما يلي:<br />- الجوع الشديد، والصداع، والغثيان، والقيء، والخمول، واضطرابات النوم، والعدوانية، والأرق، وضعف التركيز، قلة اليقظة، وبطء<br />الاستجابة، والاكتئاب، والارتباك، واضطرابات النطق والكلام، واللعثمة في الكلام، والرجفة، والشلل الجزئي، والاضطرابات الحسية،<br />والدوار، والعجز.<br />- قد تحدث الأعراض التالية كذلك: التعرُّق، ورطوبة الجلد، والقلق، وتسارع ضربات القلب، وارتفاع ضغط الدم، والخفقان، والألم القوي<br />المفاجئ في الصدر الذي قد ينتشر في المناطق المجاورة )الذبحة الصدرية، وعدم انتظام ضربات القلب(.<br />- إذا استمرت مستويات سكر الدم في الانخفاض فقد تعاني من اضطراب كبير )هذيان(، وحدوث تشنجات، وفقدان التحكم في الذات، وقد<br />يصبح التنفس سطحيًّا، وتنخفض ضربات القلب، وقد تصاب بفقدان الوعي. قد تشبه الصورة السريرية للانخفاض الشديد في سكر الدم<br />أعراض الإصابة بالسكتة الدماغية.<br />علاج نقص سكر الدم:<br />في معظم الحالات تختفي أعراض انخفاض السكر في الدم بسرعة كبيرة عند تناول شكل من أشكال السكر، على سبيل المثال: مكعبات سكر<br />أو عصير مُحلى أو شاي مُحلى. اتَّصل بطبيبك أو اذهب إلى المستشفى إذا لم يُساعدك تناول جرعة من السكر أو إذا تكرر حدوث الأعراض.<br />&bull; رد الفعل التحسسي )بما في ذلك التهاب الأوعية الدموية، المصحوب غالبًا بطفح جلدي( والذي قد يتحول إلى ردود فعل خطيرة مع صعوبة في<br />التنفس، وانخفاض في ضغط الدم، وأحيانًا تتحول إلى صدمة. في حالة حدوث طفح جلدي يجب إخطار الطبيب على الفور.<br />&bull; حساسية )فرط التحسس( في الجلد مثل: )الحكة، والطفح الجلد، وزيادة الحساسية للشمس(، وقد تتحول بعض ردود الفعل التحسسية البسيطة<br />إلى ردود فعل تحسسية خطيرة.<br />&bull; وظائف كبد غير طبيعية تتضمن إصفرار البشرة والعينين )اليرقان( أو مشاكل في تدفُّق الصفراء )ركود صفراوي(، أو زيادة إنزيمات<br />الكبد، أو التهاب الكبد أو فشل الكبد.<br />&bull; اضطرابات الهضم: الشعور بالغثيان أو الإسهال أو الشعور بالامتلاء أو الانتفاخ، أو آلام في البطن وفقدان الشهية.<br />&bull; اضطرابات التذوق: الشعور بطعم معدني في الفم.<br />&bull; اضطرابات الدم: انخفاض عدد خلايا الدم.<br />&bull; انخفاض في عدد الصفائح الدموية )التي تزيد من خطر النزيف أو الكدمات؛ بما في ذلك: النزيف الحاد غير المعتاد أو كدمات تحت الجلد(.<br />- كرات الدم البيضاء )وهو ما يُمكن أن يزيد من احتمالية الإصابة بالعدوى(.<br />- كرات الدم الحمراء )وهو ما قد يجعل البشرة شاحبة ويسبب الضعف أو صعوبة التنفس(.<br />وبشكلٍ عام تتحسن تلك المشكلات بعد التوقُّف عن تناول أماجلايم-مت.<br />&bull; انخفاض في مستوى كمية الصوديوم في الدم )يظهر عن طريق إجراء اختبارات الدم(.<br />&bull; انخفاض في مستويات فيتامين ب 12 : قد يحدث انخفاض في مستويات فيتامين ب 12 . لذلك يجب مراقبة مستويات فيتامين ب 12 عند الحاجة.<br />&bull; اضطرابات العين: قد تحدث مشاكل في الرؤية عند بدء العلاج بأماجلايم-مت</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يُحفظ هذا الدواء بعيدًا عن متناول أيدي ومرأى الأطفال.<br />&bull; يُحفظ في درجة حرارة أقل من 30 درجة مئويَّة.<br />&bull; يجب عدم استخدام الدواء بعد تاريخ الانتهاء المُوضَّح على العبوة والشريط. يُشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.<br />&bull; يجب عدم التخلُّص من الأدوية في مياه الصرف الصحي أو قمامة المنزل. اسأل الصيدلي عن كيفية التخلُّص من الأدوية التي لم تَعُدْ بحاجة<br />إلى استخدامها؛ لأن هذه التدابير تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما يحتوي عليه أماجلايم-مت<br />&bull; المواد الفعَّالة هي جليميبيريد 2 ملغم وميتفورمين هيدروكلورايد 500 ملغم.<br />وسترات الماغنسيوم وأوبادري K &bull; المكونات الأخرى هي السيليلوز دقيق التبلور وكروسبوفيدون وغليكولات النشاء الصودي والبوفيدون 30<br />أبيض ولاكتوز أحادي الإماهة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف يبدو أماجلايم-مت؟ وما هي محتويات العبوة؟<br />على جانب واحد، &raquo;C26&laquo; أقراص أماجلايم-مت المغلّفة هي أقراص بيضاء مُغلَّفة لها شكل الكبسولة ومُحدَّبة من الجانبين، محفور عليها<br />وخالية من النقوش على الجانب الآخر.<br />مُعبأة في 4 شرائط ) 7 أقراص في كل شريط(.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>شركة الشرق الأوسط للصناعات الدوائية المحدودة</p><p>(أفالون فارما)</p><p>ص.ب. 4180 الرياض 11491</p><p>المدينة الصناعية الثانية، الرياض، المملكة العربية السعودية</p><p>هاتف</p><p>0966112653948 &ndash; 00966112653427</p><p>فاكس</p><p>00966112654723</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            08/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amaglime-Met 2/500 mg film-coated tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains Glimepiride 2mg and Metformin hydrochloride 500mg
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Amaglime-Met 2/500 mg film-coated tablet are white capsule shaped, biconvex filmcoated tablet
debossed with “C26” on one side and plain on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the management of patients with type 2 diabetes mellitus when diet, exercise and single agent (glimepiride<br />or metformin alone) do not result in adequate glycaemic control.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In principle, the dosage of Amaglime-Met is governed by the desired blood glucose level. The dosage of<br />Amaglime-Met must be the lowest which is sufficient to achieve the desired metabolic control. During treatment<br />with Amaglime-Met glucose levels in blood and urine, must be measured regularly. In addition, it is<br />recommended that regular determinations of the proportion of glycated hemoglobin be carried out. Mistakes,<br />e.g. forgetting to take a dose, must never be corrected by subsequently taking a larger dose. Measures for<br />dealing with such mistakes (in particular forgetting a dose or skipping a meal) or situations where a dose<br />cannot be taken at the prescribed time must be discussed and agreed between physician and patient<br />beforehand.<br />As an improvement in control of diabetes is, in itself, associated with higher insulin sensitivity, glimepiride<br />requirements may fall as treatment proceeds. To avoid hypoglycaemia timely dose reduction or cessation of<br />Amaglime-Met therapy must therefore be considered. Amaglime-Met is to be administered once per day during<br />breakfast or the first main meal. The highest recommended dose per day should be 8mg of glimepiride and<br />2000mg of metformin.<br />Daily doses of glimepiride of more than 6mg are more effective only in a minority of patients. In order to avoid<br />hypoglycaemia, the starting dose of Amaglime-Met should not exceed the daily doses of glimepiride or<br />metformin already being taken.<br />When switching from combination therapy of glimepiride plus metformin as separate tablets, Amaglime-Met<br />should be administered on the basis of dosage currently being taken.<br />Titration:<br />The daily dose should be titrated based on the glycaemic control, in increments of 1 tablet only, corresponding<br />to the lowest strength.<br />Duration of therapy:<br />Treatment with Amaglime-Met is normally a long-term therapy.<br />Special Populations:<br />Children<br />Data are insufficient to recommend paediatric use of Amaglime-Met.</p><p>Renal impairment<br />A GFR should be assessed before initiation of treatment with metformin containing products and at least<br />annually thereafter. In patients at increased risk of further progression of renal impairment and in the elderly,<br />renal function should be assessed more frequently, e.g. every 3-6 months. The maximum daily dose of<br />metformin should preferably be divided into 2-3 daily doses.<br />Factors that may increase the risk of lactic acidosis (see Section Warnings) should be reviewed before<br />considering initiation of metformin in patients with GFR&lt;60 mL/min.<br />If no adequate strength of Amaglime-Met is available, individual mono-components should be<br />used instead of the fixed dose combination.</p><p>Amaglime-Met must be swallowed whole and not crushed&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                For Glimepiride:
 in patients hypersensitive to glimepiride, other sulfonylureas, other sulphonamides, or any of the
excipients of Amaglime-Met
 in pregnant women.
 in breast-feeding women.
No experience has been gained concerning the use of glimepiride in patients with severe impairment of liver
function and in dialysis patients. In patients with severe impairment of hepatic function, change-over to insulin
is indicated, not least to achieve optimal metabolic control.
For Metformin:
 Hypersensitivity to metformin or any of the excipients.
 Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis, diabetic precoma).
 Severe renal failure (GFR˂30ml/min)
 Acute conditions with the potential to alter renal function such as:
‐ Dehydration
‐ Severe infection
‐ Shock
‐ Intravascular administration of iodinated contrast agents (see Precautions)
 Acute or chronic disease which may cause tissue hypoxia such as:
‐ Cardiac or respiratory failure
‐ Recent myocardial infarction
‐ Shock
-Hepatic insufficiency
‐ Acute alcohol intoxication
‐ Alcoholism
‐ Lactation
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For Glimepiride:<br />In exceptional stress situations (e.g. trauma, surgery, febrile infections) blood glucose regulation may<br />deteriorate, and a temporary change to insulin may be necessary to maintain good metabolic control.<br />For Metformin:<br /> Lactic acidosis<br />Metformin accumulation occurs at acute worsening of renal function and increases the risk of<br />lactic acidosis.<br />In case of dehydration (severe diarrhea or vomiting, fever or reduced fluid intake), metformin should be<br />temporarily discontinued and contact with a health care professional is recommended.<br />Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and NSAIDs)<br />should be initiated with caution in metformin-treated patients. Other risk factors associated to lactic acidosis are<br />excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting,<br />and any conditions associated with hypoxia as well as concomitant use of medicinal products that may cause<br />lactic acidosis (see Section Contraindications and Section Interactions).<br />Diagnosis:<br />Patients and/or caregivers should be informed of the risk of lactic acidosis. In case of suspected symptoms, the<br />patient should stop taking metformin and seek immediate medical attention. Diagnostic laboratory findings are<br />decreased blood pH, (˂7.35), increased plasma lactate levels (˃ 5 mmol/L), and an increased anion gap and<br />lactate/pyruvate ratio.<br />Renal function:<br />GFR should be assessed before treatment initiation and regularly thereafter (see Section Dosage and<br />Administration).<br />Metformin is contraindicated in patients with GFR&lt;30 ml/min and should be temporarily discontinued in the<br />presence of conditions that alter renal function, (see Section Contraindications).<br />Decreased renal function in elderly subjects is frequent and asymptomatic. Special caution should be exercised<br />in situations where renal function may become impaired, for example when initiating antihypertensive therapy<br />or diuretic therapy and when starting therapy with an NSAID.<br />Administration of iodinated contrast agent:<br />Intravascular administration of iodinated contrast agents may lead to contrast induced nephropathy, resulting in<br />metformin accumulation and an increased risk of lactic acidosis.<br />Metformin should be discontinued prior to, or at the time of the imaging procedure and not restarted until 48<br />hours after, provided that renal function has been re-evaluated and found to be stable (see Section Dosage<br />and Administration and Section Interactions).</p><p>Surgery:<br />Metformin must be discontinued at the time of surgery under general, spinal or epidural anesthesia. Therapy<br />may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that<br />renal function has been re-evaluated and found to be stable.<br />PRECAUTIONS<br />For Glimepiride:<br />In the initial weeks of treatment, the risk of hypoglycemia may be increased and necessitates especially careful<br />monitoring. Factors favoring hypoglycemia include:<br /> unwillingness or (more commonly in older patients) incapacity of the patient to cooperate.<br /> undernourishment, irregular mealtimes or skipped meals.<br /> imbalance between physical exertion and carbohydrate intake.<br /> alterations of diet.<br /> consumption of alcohol, especially in combination with skipped meals.<br /> impaired renal function.<br /> severe impairment of liver function.<br /> overdosage with glimepiride.<br /> certain uncompensated disorders of the endocrine system affecting carbohydrate metabolism or<br />counter-regulation of hypoglycaemia (as for example in certain disorders of thyroid function and in<br />anterior pituitary or corticoadrenal insufficiency).<br /> concurrent administration of certain other medicines (see Interactions).<br /> treatment with glimepiride in the absence of any indication.<br />If such risk factors for hypoglycemia are present, it may be necessary to adjust the dosage of glimepiride or the<br />entire therapy. This also applies whenever illness occurs during therapy or the patient&#39;s life-style changes.<br />Those symptoms of hypoglycemia which reflect the body&#39;s adrenergic counter regulation (see Adverse<br />Reactions) may be milder or absent where hypoglycemia develops gradually, in the elderly, and where there is<br />autonomic neuropathy or where the patient is receiving concurrent treatment with beta-blockers, clonidine,<br />reserpine, guanethidine or other sympatholytic drugs.<br />Hypoglycemia can almost always be promptly controlled by immediate intake of carbohydrates (glucose or<br />sugar). It is known from other sulfonylureas that, despite initially successful countermeasures, hypoglycemia<br />may recur. Patients must, therefore, remain under close observation. Severe hypoglycemia further requires<br />immediate treatment and follow-up by a physician and, in some circumstances, in-patient hospital care.<br />Treatment of patients with G6PD-deficiency with sulfonylurea agents can lead to hemolytic anemia. Since<br />glimepiride belongs to the class of sulfonylurea agents, caution should be used in patients with G6PDdeficiency<br />and a non-sulfonylurea alternative should be considered.</p><p>For Metformin:<br />Regular monitoring of thyroid-stimulating hormone (TSH) levels is recommended in patients with<br />hypothyroidism (see Adverse reactions)<br />Long-term treatment with metformin has been associated with a decrease in vitamin B12 serum levels which<br />may cause peripheral neuropathy. Monitoring of the vitamin B12 level is recommended (see Adverse reactions)</p><p>Other precautions:<br /> All patients should continue their diet with a regular distribution of carbohydrate intake during the day.<br />Overweight patients should continue their energy-restricted diet.<br /> The usual laboratory tests for diabetes monitoring should be performed regularly.<br /> Metformin alone never causes hypoglycemia, although caution is advised when it is used in<br />combination with insulin or sulfonylureas.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For Glimepiride:<br />Based on experience with glimepiride and on what is known of other sulfonylureas, the following interactions<br />must be considered:<br />Glimepiride is metabolized by cytochrome P450 2C9 (CYP2C9). This should be taken into account when<br />glimepiride is co-administered with inducers (e.g. rifampicin) or inhibitors (e.g. fluconazole) of CYP2C9.<br />Potentiation of the blood-glucose-lowering effect and, thus, in some instance&rsquo;s hypoglycemia<br />may occur when one of the following drugs is taken, for example: insulin and other oral antidiabetics; ACE<br />inhibitors; anabolic steroids and male sex hormones; chloramphenicol; coumarin derivatives;<br />cyclophosphamide; disopyramide; fenfluramine; fenyramidol; fibrates; fluoxetine; guanethidine; ifosfamide;<br />MAO inhibitors; miconazole; fluconazole; paraaminosalicylic acid; pentoxifylline (high dose parenteral);<br />phenylbutazone; azapropazone; oxyphenbutazone; probenecid; quinolones; salicylates; sulfinpyrazone;<br />clarithromycin; sulfonamide antibiotics; tetracyclines; tritoqualine; trofosfamide.<br />Weakening of the blood-glucose-lowering effect and, thus raised blood glucose levels may occur when one of<br />the following drugs is taken, for example: acetazolamide; barbiturates; corticosteroids; diazoxide; diuretics;<br />epinephrine (adrenaline) and other sympathomimetic agents; glucagon; laxatives (after protracted use);<br />nicotinic acid (in high doses); estrogens and progestogens; phenothiazines; phenytoin; rifampicin; thyroid<br />hormones.<br />H2 receptor antagonists, beta-blockers, clonidine and reserpine may lead to either potentiation or<br />weakening of the blood glucose-lowering effect.<br />Under the influence of sympatholytic drugs such as beta-blockers, clonidine, guanethidine and reserpine, the<br />signs of adrenergic counter-regulation to hypoglycemia may be reduced or absent.<br />Both acute and chronic alcohol intake may potentiate or weaken the blood glucose-lowering action of<br />glimepiride in an unpredictable fashion. The effect of coumarin derivatives may be potentiated or weakened.<br />Bile acid sequestrant: Colesevelam binds to glimepiride and reduces glimepiride absorption from the<br />gastrointestinal tract. No interaction was observed when glimepiride was taken at least 4 hours before<br />colesevelam. Therefore, glimepiride should be administered at least 4 hours prior to colesevelam.<br />For Metformin:<br />Concomitant use not recommended:<br />Alcohol: Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in case of fasting<br />or malnutrition or hepatic insufficiency.<br />Avoid consumption of alcohol and alcohol-containing medications.<br />Iodinated contrast agents<br />Metformin must be discontinued prior to, or at the time of the image procedure and not restarted<br />until at least 48 hours after, provided that renal function has been re-evaluated and found to be<br />stable (See Section Dosage and Administration and Warnings).</p><p>Combinations requiring precautions for use:<br />Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g.<br />NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor<br />antagonists and diuretics, especially loop diuretics. When starting or using such products in combination with<br />metformin, close monitoring of renal function is necessary.<br />Glucocorticoids (systemic and local routes), beta-2-agonists and diuretics have intrinsic hyperglycemic activity.<br />Inform the patient and perform more frequent blood glucose monitoring, especially at the beginning of<br />treatment. If necessary, adjust the dosage of the antidiabetic drug during therapy with the other drug and upon<br />its discontinuation. ACE-inhibitors may decrease the blood glucose levels. If necessary, adjust the dosage of<br />the antidiabetic drug during therapy with the other drug and upon its discontinuation.<br />Metformin may decrease the anticoagulant effect of phenprocoumon. Therefore, a close monitoring of the INR<br />is recommended.<br />Levothyroxine can reduce the hypoglycaemic effect of metformin. Monitoring of blood glucose levels are<br />recommended, especially when thyroid hormone therapy is initiated or stopped, and the dosage of metformin<br />must be adjusted if necessary.<br />Organic cation transporters (OCT)<br />Metformin is a substrate of both transporters OCT1 and OCT2.<br />Co-administration of metformin with<br />&bull; Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.<br />&bull; Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin.<br />&bull; Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprime, vandetanib, isavuconazole)<br />may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma<br />concentration.<br />&bull; Inhibitors of both OCT1 and OCT2 (such as crizotinib, olaparib) may alter efficacy and renal elimination of<br />metformin.<br />Caution is therefore advised, especially in patients with renal impairment, when these drugs are coadministered<br />with metformin, as metformin plasma concentration may increase. If needed, dose adjustment of<br />metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />For Glimepiride:<br />Glimepiride must not be taken during pregnancy. Otherwise there is risk of harm to the child. The patient must<br />change over to insulin during pregnancy.<br />Patients planning a pregnancy must inform their physician. It is recommended that such patients change over<br />to insulin.<br />For Metformin:<br />To date, no relevant epidemiological data are available. Animal studies do not indicate harmful effects with<br />respect to pregnancy, embryonal or fatal development, parturition or postnatal development.<br />When the patient plans to become pregnant and during pregnancy, diabetes should not be treated with<br />metformin, but insulin should be used to maintain blood glucose levels as close to normal as possible in order<br />to lower the risk of fatal malformations associated with abnormal blood glucose levels.<br />Lactation<br />For Glimepiride:<br />To prevent possible ingestion with the breast milk and possible harm to the child, glimepiride must not be taken<br />by breast-feeding women. If necessary, the patient must change over to insulin, or must stop breast-feeding.</p><p>For Metformin:<br />Metformin is excreted into milk in lactating rats. Similar data is not available in humans and a decision should<br />be made whether to discontinue nursing or to discontinue metformin, taking into account the importance of the<br />compound to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For Glimepiride:<br />Alertness and reactions may be impaired due to hypo- or hyperglycemia, especially when beginning or after<br />altering treatment or when glimepiride is not taken regularly. This may, for example affect the ability to drive or<br />to operate machinery.<br />For Metformin:<br />Metformin monotherapy does not cause hypoglycemia and therefore has no effect on the ability to drive or to<br />use machines.<br />However, patients should be alerted to the risk of hypoglycemia when metformin is used in combination with<br />other antidiabetic agents (sulfonylureas, insulin, repaglinide).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following CIOMS frequency rating is used, when applicable:<br />Very common &ge;10%; Common &ge;1 and &lt;10%; Uncommon &ge;0.1 and &lt;1%; Rare &ge;0.01 and &lt;0.1%; Very<br />rare&lt;0.01%, Unknown (cannot be estimated from available data).<br />For Glimepiride and Metformin<br />The use of a combination of both compounds, either as a free combination or as a fixed combination, is<br />associated with the same safety characteristics as the use of each compound separately.<br />For Glimepiride:<br /> Metabolism and nutrition disorders<br />As a result of the blood-glucose-lowering action of glimepiride, hypoglycemia may occur, which may also be<br />prolonged.<br />Possible symptoms of hypoglycemia include headache, ravenous hunger, nausea, vomiting, lassitude,<br />sleepiness, disordered sleep, restlessness, aggressiveness, impaired concentration, impaired alertness and<br />reactions, depression, confusion, speech disorders, aphasia, visual disorders, tremor, pareses, sensory<br />disturbances, dizziness, helplessness, loss of self-control, delirium, cerebral convulsions, somnolence and loss<br />of consciousness up to and including coma, shallow respiration and bradycardia.<br />In addition, signs of adrenergic counter-regulation may be present such as sweating, clammy skin, anxiety,<br />tachycardia, hypertension, palpitations, angina pectoris, and cardiac arrhythmias.<br />The clinical picture of a severe hypoglycemic attack may resemble that of a stroke.</p><p>The symptoms nearly always subside when hypoglycemia is corrected.<br /> Eye disorders<br />Especially at the start of treatment, there may be temporary visual impairment due to the change in blood<br />glucose levels. The cause is a temporary alteration in the turgidity and hence the refractive index of the lens,<br />this being dependent on blood glucose level.<br /> Gastrointestinal disorders<br />Occasionally, gastrointestinal symptoms such as nausea, vomiting, sensations of pressure or fulness in the<br />epigastrium, abdominal pain and diarrhea may occur.<br />In isolated cases, there may be hepatitis, elevation of liver enzyme levels and/or cholestasis and jaundice,<br />which may progress to life-threatening liver failure but can regress after withdrawal of glimepiride.<br />Dysgeusia (frequency not known)<br /> Blood and lymphatic system disorders<br />Changes in the blood picture may occur: Rarely, thrombocytopenia and, in isolated cases, leucopenia,<br />hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis or pancytopenia may develop. Cases of<br />severe thrombocytopenia with platelet count less than 10,000/&mu;l and thrombocytopenic purpura have been<br />reported in post-marketing experience (frequency not known).<br /> Skin and subcutaneous tissue disorders<br />Alopecia (frequency not known)<br /> General disorders<br />Occasionally, allergic or pseudo-allergic reactions may occur, e.g. in the form of itching, urticaria or rashes.<br />Such mild reactions may develop into serious reactions with dyspnea and a fall in blood pressure, sometimes<br />progressing to shock. In the event of urticaria a physician must therefore be notified immediately.<br />In isolated cases, a decrease in serum sodium concentration and allergic vasculitis or hypersensitivity of the<br />skin to light may occur.<br /> Investigations<br />Glimepiride, like all sulfonylureas, can&nbsp;cause weight gain (frequency not known).</p><p>For Metformin:<br />Gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal pain and loss of appetite (&gt;10%) are<br />very common: these occur most frequently during initiation of therapy and resolve spontaneously in most<br />cases. To prevent these gastrointestinal symptoms, it is recommended that metformin be taken in 2 or 3 daily<br />doses during or after meals. A slow increase of the dose may also improve gastrointestinal tolerability.</p><p>- Metallic taste (3%) is common.<br />- Mild erythema has been reported in some hypersensitive individuals. The incidence of such effects is<br />regarded as very rare (&lt;0.01%).<br />- A decrease of vitamin B12 absorption with decrease of serum levels has been observed in patients treated<br />long-term with metformin and appears generally to be without clinical significance (&lt;0.01%).<br />However, cases of peripheral neuropathy in patients with vitamin B12 deficiency have been reported in postmarketing<br />experience (frequency not known) (see Precautions)<br />-Lactic acidosis (0.03 cases/1000 patient-years) is very rare (see Warnings).<br />- Hemolytic anemia (frequency unknown)<br />- Reduction of thyrotropin level in patients with hypothyroidism (see Precautions) (frequency unknown)<br />- Hypomagnesemia in the context of diarrhea (frequency unknown)<br />- Encephalopathy (frequency unknown)<br />- Photosensitivity (frequency unknown)</p><p>-Hepatobiliary disorders: Reports of liver function tests abnormalities and hepatitis resolving upon metformin<br />discontinuation</p><p>Reporting of suspected adverse reactions<br />To reports any side effect(s):<br />‐ Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966‐11‐205‐7662<br />o SFDA call center: 19999<br />o Toll free phone: 8002490000<br />o E‐mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa</p><p>Other GCC States:<br />‐ Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For Glimepiride:<br />Signs and Symptoms:<br />Acute overdosage as well as long-term treatment with too high a dose of glimepiride may lead to severe lifethreatening<br />hypoglycemia.</p><p>Management:<br />As soon as an overdose of glimepiride has been discovered, a physician must be notified without delay. The<br />patient must immediately take sugar, if possible, in the form of glucose, unless a physician has already<br />undertaken responsibility for treating the overdose.<br />Careful monitoring is essential until the physician is confident that the patient is out of danger. It must be<br />remembered that hypoglycemia may recur after initial recovery.<br />Admission to hospital may sometimes be necessary - even as a precautionary measure.<br />In particular, significant overdoses and severe reactions with signs such as loss of consciousness or other<br />serious neurological disorders are medical emergencies and require immediate treatment and admission to<br />hospital.<br />If, for example, the patient is unconscious, an intravenous injection of concentrated glucose solution is<br />indicated (for adults starting with 40 ml of 20% solution, for example). Alternatively, in adults, administration of<br />glucagon, e.g. in doses of 0.5 to 1 mg i.v., s.c. or i.m. may be considered.<br />In particular when treating hypoglycemia due to accidental intake of glimepiride in infants and young children,<br />the dose of glucose given must be very carefully adjusted in view of the possibility of producing dangerous<br />hyperglycemia and must be controlled by close monitoring of blood glucose.<br />Patients who have ingested life-threatening amounts of glimepiride require detoxification (e.g. by gastric lavage<br />and medicinal charcoal).<br />After acute glucose replacement has been completed it is usually necessary to give an intravenous glucose<br />infusion in lower concentration so as to ensure that the hypoglycemia does not recur.<br />The patient&#39;s blood glucose level should be carefully monitored for at least 24 hours. In severe cases with a<br />protracted course, Hypoglycemia, or the danger of slipping back into hypoglycemia, may persist for several<br />days.<br />For Metformin:<br />hypoglycemia has not been seen with metformin doses of up to 85 g, although lactic acidosis has occurred in<br />such circumstances. High overdose or concomitant risks of metformin may lead to lactic acidosis. Lactic<br />acidosis is a medical emergency and must be treated in hospital. The most effective method to remove lactate<br />and metformin is hemodialysis.<br />Pancreatitis may occur in the context of a metformin overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amaglime-Met is a combined hypoglycemic medicine, which is composed of glimepiride<br />and metformin.<br />Pharmacodynamics of glimepiride<br />Glimepiride, one of the active substances of Amaglime-Met, is an oral hypoglycemic medicine -<br />sulfonylureas of the III generation.<br />Glimepiride stimulates secretion and release of insulin from the pancreas beta-cells (pancreatic<br />effect), improves sensitivity of peripheral tissues (muscle and fat) to the action of endogenous<br />insulin (extrapancreatic action).</p><p>Effect on insulin secretion<br />Sulfonylureas increase insulin secretion by closing the ATP-dependent potassium channels, located in the<br />cytoplasmic membrane of pancreatic beta-cells. By closing the potassium channels, they cause depolarization<br />of the beta-cells, thus facilitating opening of calcium channels and increasing of transmission of calcium into the<br />cells. Glimepiride is bounded and unbounded from the protein of pancreatic beta cells at a high replacement<br />rate of (mol. mass -65 kD/SURX), which is associated with the ATP-dependent potassium channels, however it<br />is different from the binding sites of conventional sulfonylureas (protein with mol. mass &ndash; 140 kD/SUR1).<br />This process leads to release of insulin by exocytosis, and the amount of secreted insulin is significantly lesser<br />than with sulfonylureas of II generation (e.g. glibenclamide). Minimum stimulating effect of glimepiride on insulin<br />secretion is provided and there is a lower risk of development of hypoglycemia.<br />Extrapancreatic activity<br />As with traditional sulfonylureas, but to a greater extent, glimepiride has pronounced extrapancreatic effects<br />(reduction of insulin resistance, antiatherogenic, antiplatelet and antioxidant action).<br />Utilization of glucose by peripheral tissues (fat and muscle) occurs via specific transporter proteins (GLUT1 and<br />GLUT4), located in the cell membranes. Transportation of glucose in these tissues in diabetes mellitus type 2 is<br />limited in rate of glucose utilization stage. Glimepiride very rapidly increases the number and activity of<br />molecules, glucose transporter (GLUT1 and GLUT4), which leads to an increase in glucose uptake by<br />peripheral tissues.<br />Glimepiride has a weak inhibitory effect on ATP-sensitive potassium channels of cardiomyocytes. Upon<br />administration of glimepiride, the ability of metabolic adaptation to myocardial ischemia is preserved.<br />Glimepiride increases the activity of phospholipase C, which results reduction of intracellular calcium<br />concentration in muscle and fat cells, causing decrease in the activity of proteinkinase A, which in turn, leads to<br />lead to stimulation of glucose metabolism.<br />Glimepiride inhibits hepatic glucose output by increasing the intracellular concentration of fructose-2,6-<br />bisphosphate, which in turn inhibits gluconeogenesis.<br />Glimepiride selectively inhibits cyclooxygenase and reduces conversion of arachidonic acid to thromboxane A2,<br />important endogenous factor for platelet aggregation.<br />Glimepiride reduces the lipid content, significantly decreases lipid peroxidation and promotes its<br />anti-atherogenic effect.<br />Glimepiride increases the content of endogenous Q-tocopherol, activity of catalase, glutathione peroxidase and<br />superoxide dismutase, thereby reducing the severity of oxidative stress, always presented in the body of the<br />patient with diabetes mellitus type 2.<br />Pharmacodynamics of metformin<br />Metformin is a hypoglycemic medicine from the biguanide group. Its hypoglycemic effect is possible only under<br />condition of preservation of insulin secretion (although reduced).<br />Metformin has no effect on the beta-cells of the pancreas and does not increase secretion of insulin. Metformin<br />at therapeutic doses do not cause hypoglycemia in humans. The mechanism of action of metformin is not yet<br />completely learnt. It is assumed that metformin may potentiate the effects of insulin or that it can increase the<br />effects of insulin receptors in peripheral areas.<br />Metformin increases insulin sensitivity due to increase in the number of insulin receptors on cell surface<br />membranes. Besides metformin inhibits gluconeogenesis in the liver, reduces formation of free fatty acids and<br />fat oxidation, reduces the concentration of triglyceride (TG) and low-density lipoproteids (LDL) and very lowdensity<br />lipoprotein (VLDL) in blood.<br />Metformin slightly reduces appetite and decreases absorption of carbohydrates in the intestine.<br />It improves blood fibrinolytic properties due to suppression of tissue plasminogen activator inhibitor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetics of glimepiride<br />With multiple daily dose of 4 mg glimepiride, maximum serum concentration (Cmax) is achieved after about 2.5<br />hours and is 309 ng / ml; there is a linear relationship between dose and Cmax, as well as between the dose<br />and AUC (area under plasma &ldquo;concentration &ndash; time&rdquo; curve). When administered, bioavailability of glimepiride is&nbsp;almost complete. Food intake has no significant effect on absorption, with the exception of a slight slow-down<br />of the rate of absorption.<br />Glimepiride is characterized by a very low distribution volume (approximately 8.8 liters), approximately equal to<br />the albumin distribution volume, high plasma protein binding level (99%) and low clearance (about 48 ml/min).<br />After a single oral administration of glimepiride, 58% of the dose is excreted by the kidneys (as metabolites)<br />and 35% of the dose is excreted through the intestines. Half-life in case of plasma concentrations of glimepiride<br />in plasma, corresponding to the multiple administration, is 5-8 hours. After administration of high dose, half-life<br />increases slightly.<br />In urine and faeces two inactive metabolites are revealed, resulting the metabolism in the liver, one of them is<br />hydroxy derivative, and the other - carboxy derivative. After oral administration of glimepiride, terminal half-life<br />of these metabolites is 3-5 hours and 5-6 hours, respectively.<br />Glimepiride is excreted in breast milk and crosses the placental barrier. Glimepiride poorly crosses the bloodbrain<br />barrier.<br />Comparison of single and multiple (2 times daily) administration of glimepiride did not reveal significant<br />differences in the pharmacokinetic parameters and their variability between patients was insignificant.<br />Significant accumulation of glimepiride was absent.<br />Pharmacokinetic parameters of glimepiride are the same for patients of different genders and various ages.<br />In patients with impaired renal function (low creatinine clearance) tended to increase clearance of glimepiride<br />and decrease in its average concentrations in the blood serum, which is likely caused by a more rapid<br />clearance of glimepiride due to its lower binding to plasma proteins. Thus, there is no additional risk of<br />accumulation of glimepiride in such categories of patients.<br />Pharmacokinetics of metformin<br />Metformin is absorbed from the gastrointestinal tract adequately after oral administration. Absolute<br />bioavailability is 50-60%. Cmax, composed of average 2 mg/ml, is reached after 2.5 hours. In case of<br />simultaneous food intake, absorption of metformin is reduced and slowed down.<br />Metformin is rapidly distributed into the tissue, practically does not bind to plasma proteins. It is metabolized to<br />a very small extent and excreted by the kidneys. The clearance in healthy subjects is 440 ml/min (4 times<br />greater than that of creatinine), indicating presence of active tubular secretion of metformin. Half-life of<br />metformin is approximately 6.5 hours.<br />There is a risk of metformin accumulation in case of renal insufficiency.<br />Pharmacokinetics Amaglime-Met with the fixed dose of glimepiride and metformin<br />In case of administration of fixed dose of the combined drug Amaglime-Met (tablet containing glimepiride 2 mg<br />+ metformin 500 mg), Cmax and AUC values correspond to bioequivalence criteria when compared to the<br />same parameters in case of administration of the same combination as separate preparations (tablet of<br />glimepiride 2 mg and metformin 500 mg).<br />In addition, dose-proportional increase of Cmax and AUC of glimepiride was shown by increasing<br />the dose from 1 mg to 2 mg in the combined fixed-dose preparations with a constant dose of<br />metformin (500 mg) in the composition of these preparations.<br />No other significant differences are observed in safety, including profile of adverse effects in patients taking<br />the drug Amaglime-Met 1 mg +500 mg, and the patients taking the drug Amaglime-Met 2 mg +500 mg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core: Microcrystalline Cellulose, Crosspovidone, Sodium Starch Glycolate and Povidone K30,<br />Magnesium Stearate and Lactose Monohydrate<br />Tablet coating: Hypromellose, Polyethylene Glycol /Marcogol, Titanium Dioxide and Carnauba Wax.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear (PVC/PE/PVdC 90 GSM) - Aluminum blister.<br />28 film coated tablets, packed in 4 blisters (7 tablets / blister).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Middle East Pharmaceutical Industries Co. Ltd (Avalon-Pharma)
2nd industrial City, P.O.Box 4180 Riyadh 11491, Kingdom of Saudi Arabia
Tel: 920010564, Fax: +966 (11) 2654723
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>